Phase 4 N=25 Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients
Rheumatoid Arthritis
Primary: PDUS — 28.68; 19.52; 12.17 units on a scale — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=330 Reducing the Transition From Acute to Chronic Musculoskeletal Pain Among Older Adults
Acute Musculoskeletal Pain · Chronic Pain
Primary: Mean Brief Pain Inventory-Short Form (BPI-SF) Combined Pain Severity and Interference Score — 2.67; 2.99; 2.94; 1.90 score on a scale — p=0.13
N/A N=42 Quantifying Myofascial Dysfunction in Post-Stroke Pain
Myofascial Dysfunction
Primary: T1 Rho MRI Relaxation Time of Shoulder External Rotator (Milliseconds) — 29.09; 27.15 milliseconds
N/A N=105 Prevention of Musculoskeletal Injuries in Slovenian Armed Forces
Knee Injuries and Disorders · Ankle Injuries and Disorders · Low Back Pain
Primary: Number of Soldiers With Ankle and Knee Injuries — 1; 3 Participants — p=0.134
Phase 4 N=393 Acetaminophen (APAP) +/- Oxycodone
Musculoskeletal Pain
Primary: Change in Pain Assessment — 2.9; 4.0 score on a scale
Phase 4 N=60 A Comparison of Proprietary Formulations of Oral Ketamine + Aspirin and Oral Ketamine Alone for Musculoskeletal Pain
Pain
Primary: Change in Pain Score at 60 Minutes — 2.18; 4.01 units on a scale
N/A N=207 A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection
Musculoskeletal Diseases
Primary: Musculoskeletal Adverse Events During the Musculoskeletal Disorder Follow-up Phase — 3; 3 Participants
N/A N=71 Musculoskeletal Plasticity After Spinal Cord Injury
Spinal Cord Injuries
Primary: Acute Gene Regulation: MSTN — 5.49; 4.76 arbitrary units — p=<0.001
N/A N=99 Inflammatory Abnormalities in Muscle After Stroke: Effects of Exercise
Stroke · Inflammation
Primary: Cardiovascular Fitness (VO2 Peak) — 15.9; 16.6; 21.3; 17.5 ml/kg/min — p=0.001
N/A N=23 Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty
Knee Osteoarthristis
Primary: Cross-sectional Area (CSA) of Muscle Fibers — 2680; 2377; 2028; 1882 micron squared
Phase 4 N=416 Comparative Efficacy of 4 Oral Analgesics
Pain
Primary: Between Group Difference in Change in Numerical Rating Scale (NRS) Pain Scores — 4.4; 3.5; 3.9; 4.3 units on a scale
Phase 2 N=90 Ibuprofen Versus Acetaminophen vs Their Combination in the Relief of Musculoskeletal Pain in the Emergency Setting
Pain
Primary: Pain Severity — 39; 43; 42 mm
Phase 4 N=240 Orphenadrine and Methocarbamol for LBP
Low Back Pain
Primary: Functional Impairment as Measured on the Roland Morris Disability Questionnaire — 10.9; 9.4; 8.1 units on a scale
Phase 3 N=24 Arimoclomol in Sporadic Inclusion Body Myositis
Inclusion Body Myositis
Primary: Count of Adverse Events Reported — 109; 52 adverse events reported
Phase 2 N=164 Bonipar for Acute and Chronic Musculoskeletal Pain
Chronic Pain · Musculoskeletal Pain
Primary: Change in Pain as Measured by Subjective Pain Intensity Rating (SPIR) — -2.3; -2.6 score on a scale — p=0.46
Phase 4 N=110 Intramuscular Ketorolac at Two Single-Dose Regimens
Musculoskeletal Pain · Analgesia · Adverse Event
Primary: Mean Difference of Visual Analog Scale Scores — -29.74; -29.85 score on a scale
N/A N=38 Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections
Musculoskeletal Infection · Acute Hematogenous Osteomyelitis · Septic Arthritis
Primary: Number of Participants With a Pathogen Identified by the Initial Karius Test (IP1) and Standard Culture Methods — 23; 26; 15 Participants
Phase 4 N=1 Intra-articular Doxycycline: A Novel Treatment of Adhesive Capsulitis
Adhesive Capsulitis · Adhesive Capsulitis of Unspecified Shoulder · Frozen Shoulder
Primary: Change in American Shoulder and Elbow Score (ASES)
N/A N=128 Subacute Low Back Pain in Active Duty
Subacute Low Back Pain
Primary: Lower Back Strength-Extension — 54.5; 50.2; 49.2; 57.5 kg-Force
N/A N=1,389 PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders
Rheumatic Diseases · Arthralgia · Myalgias/Myopathy
Primary: Visual Analog Scale (VAS) — 6.57; 4.23; 2.61 units on a scale
Phase 4 N=323 A Randomized Study of Three Medication Regimens for Acute Low Back Pain
Acute Low Back Pain
Primary: Change in Functional Disability as Measured by the Roland Morris Disability Questionnaire — 5; 4; 7 units on a scale
N/A N=22 Diagnosing Intensive Care Unit (ICU) Acquired Weakness
ICU Acquired Weakness
Primary: Peak Acceleration Measured in Extensor Carpi Radialis Longus — 0.476; 1.639; 0.541; 1.608 units of Gravity
Phase 4 N=54 Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab
Rheumatoid Arthritis
Primary: Baseline to Month 3 Change in Total Power Doppler Synovitis Score of 34 Joints (Range 0 - 102) — 6.84 units on a scale
N/A N=8 7 Tesla MRI Study in Patients With Statin Related Muscle Complaints
Statin-related Muscle Pain · Muscle Aches · Muscle Weakness
Primary: Change in Pre- and Post-phosphocreatine Relaxation Time — 5.58; 5.083 milliseconds
Phase 2 N=244 Musculoskeletal Effects of Bicarbonate
Muscle Loss · Fractures · Osteoporosis, Age Related
Primary: The Dose of Potassium Bicarbonate Needed for Maximal Suppression of 24-hr Urinary N-telopeptide — 240; 230; 241; -53 nmol/day
N/A N=89 (MIST1)-Part 1: Assessment & Feasibility of Post-Symptoms Evaluation
Patient Safety · Manipulation, Spinal
Primary: Number of Patient Encounters That Report a New or Worsening Symptom — 8 Participants
N/A N=34 Acetaminophen and Impaired Musculoskeletal Adaptations to Exercise Training
Sarcopenia · Osteoporosis · Aging
Primary: Change in Total Body Fat-free Mass — 1.5; 2.3; 0.7 kg — p=0.38
Phase 4 N=399 Colchicine Or Naproxen Treatment for ACute gouT
Gout
Primary: Change in Pain Intensity — 3.5; 3.8 units on a scale
Phase 3 N=139 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis
Juvenile Dermatomyositis
Primary: Responder Status Defined as 20% Improvement in at Least 3 Core Set Variables With no More Than 1 of the Remaining Variables, (Muscle Strength Excluded), Worsened by >…
Phase 3 N=100 The Use of Methylsulfonylmethane (MSM) in the Treatment of Low Back Pain
Low Back Pain
Primary: Pain Level — 3.4; 3.7; 2.8; 2.9 score on a scale